MedTrace Logo

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

NCT04200625 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-05-10

No results posted yet for this study

Summary

Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

Conditions

  • Epicardial Fat

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Gianluca Iacobellis, MD PhD · University of Miami

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-24
Primary Completion
2019-12-09
Completion
2019-12-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04200625 on ClinicalTrials.gov